Oxford, UK – 18 September 2025 – The partnership between OGT, a global leader in genomic research and diagnostic solutions, and QIAGEN Digital Insights (QDI), a leading provider of genomic interpretation and analysis tools, expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq™ NGS panels. Purpose-built for variant interpretation and clinical reporting, QCI Interpret delivers AI-powered, expert-curated classifications along with oncologist-reviewed summaries and transparent evidence links. Through this collaboration, SureSeq™ NGS panel users gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
QDI has built the world’s largest expert-curated knowledge base of genomic and bioinformatic content, serving as the foundation of QCI Interpret. By combining the clinical precision of expert (MD/PhD) curation with the speed and scalability of AI-powered automation, QCI Interpret enables labs to deliver high-confidence variant interpretation and reporting. QCI Interpret empowers SureSeq customers with transparent variant classifications, oncologist-reviewed summaries, and on-demand interpretations—streamlining the path from sequencing to final report.
OGT’s suite of SureSeq NGS products has been developed with superior hybridisation-based detection capabilities to ensure clinical research labs effortlessly achieve comprehensive genomic profiling of their samples and minimise the risk of missing variants. Combined with the unmatched accuracy and consistency of QIAGEN’s proprietary software, labs gain access to an end-to-end workflow for faster, better-informed and more confident insights.
Gareth Thomson, Executive Vice President of Commercial Operations at OGT, commented “We are delighted to be partnering with QIAGEN Digital Insights to allow OGT’s customers to package their SureSeq NGS panels with QIAGEN Digital Insights tertiary analysis software creating an end-to-end NGS workflow with access to the world’s largest knowledge base increasing customers confidence in variant classification. This partnership is an important demonstration of OGT’s commitment to providing the most relevant and impactful oncology insights”.
“We are pleased to partner with OGT to deliver an even greater impact to labs worldwide,” said Nitin Sood, Senior Vice President and head of Life Sciences at QIAGEN. “This collaboration reinforces QIAGEN Digital Insights’ global leadership in variant interpretation to deliver scalable, collaborative and cutting-edge solutions for precision medicine. As labs face mounting challenges with the complexity and volume of NGS testing, QDI is uniquely positioned to support SureSeq workflows with transparent variant classifications, oncologist-reviewed insights and flexible reporting. This helps customers to scale confidently, reduce turnaround times, and improve outcomes for patients.”
As part of Sysmex, the world’s largest haematology diagnostics provider, OGT’s partnership with QIAGEN further progresses the shared mission of improved diagnostics and testing, bringing expertise together to support labs and researchers to shape the advancement of healthcare.
More information on the OGT’s SureSeq NGS products can be found here: https://www.ogt.com/products/technology/sureseq-ngs/
More information on the QIAGEN Digital Insights can be found here: https://digitalinsights.qiagen.com/
